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Tomoki Utsumi, MD, PhD,a Yoshihisa Kadota, MD, PhD,a Takuma Nasu, MD, PhD,b Katsuyuki Aozasa, MD, PhD,b and
Meinoshin Okumura, MD, PhDaObjective: Recent technologic developments in computed tomography have in-
creased the incidence of surgical intervention for small-sized lung cancer. Although
indications of a sublobar resection for early disease have been discussed, we occasion-
ally encounter locally advanced small-sized lung cancer with node metastasis. The
present study aimed to clarify the histopathologic factors influencing nodal involve-
ment and prognosis of such patients.
Methods:We studied 97 patients who underwent complete resection for an adenocar-
cinoma of 2 cm or less in diameter. Lymph node metastasis and necrosis were micro-
scopically evaluated, whereas immunohistochemical studies were also performed
with Ki-67 and D2-40 for proliferation activity and lymphatic invasion, respectively.
In addition, carcinoembryonic antigen expression in the tumor and its level in serum
were investigated. Survival analysis was then conducted by using these clinicopath-
ologic factors.
Results: The 5-year disease-free survival rate was 90%. Nodal involvement was sig-
nificantly frequent in patients with tumors showing microscopic necrosis, a Ki-67
labeling index of greater than 5%, and an increased serum carcinoembryonic antigen
level. Furthermore, 5-year disease-free survival was worse in patients with lesions
showing microscopic necrosis (68%), a Ki-67 labeling index of greater than 5%
(76%), and lymphatic invasion detected with D2-40 staining (77%). Multivariate
analysis identified lymphatic invasion detected with D2-40 to be an independent
predictor for postoperative recurrence.
Conclusions: These results indicate that microscopic necrosis, Ki-67 labeling index,
and serum carcinoembryonic antigen level are predictors of nodal involvement. Care-
ful postoperative follow-up examinations for recurrence are required for patients with
tumors that show microscopic necrosis, high Ki-67 labeling index, and lymphatic
invasion, even in those with stage IA disease.
W
ith the development of high-resolution computed tomography (CT) and its
application for cancer screening, small-sized peripheral lung cancer is
more frequently encountered. A bronchioloalveolar carcinoma that shows
ground-glass opacity (GGO) in CT imaging without vessel or lymphatic spread deter-
mined histologically has been recognized as a less-invasive subgroup of small-sized
adenocarcinomas.1,2 The Noguchi classification, which was first reported in 1995 and
is popular in Japan, classifies peripheral adenocarcinomas as those of 2 cm or less in
diameter.3 Because of their low-grade malignant feature, several studies have evalu-
ated the results of a lesser pulmonary resection by using preoperative information in
regard to GGO area or tumor diameter and found it to be safe on the basis of similar
outcomes compared with outcomes in patients who underwent a lobectomy.4-7 How-
ever, it is well known that lymph node metastasis is not rare in patients with lung
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cancer with tumors smaller than 2 cm because the frequency
of nodal involvement was reported to be 15% to 28% for
tumors sized 2 cm or less and 15% for solid subcentimeter
lesions.8-10 Thus it is important to identify patients with
locally advanced cancer with nodal metastasis originating
from small-sized lung cancer to make proper decisions
regarding operative mode and adjuvant treatment.
In the present study we analyzed several potential prog-
nostic factors, including histologic necrosis, Ki-67 labeling
index (LI), carcinoembryonic antigen (CEA) expression, se-
rum CEA level, and degree of lymphatic invasion based on
the D2-40 antibody for lymphangioendothelium, in patients
with a pulmonary adenocarcinoma of 2 cm or less in diame-
ter. Furthermore, we evaluated the capability of those factors
to predict advanced disease with a worse outcome before or
during the operation. We believe that the clinicopathologic
predictors revealed in the present study can contribute to
the improvement of outcome in patients with a small-sized
adenocarcinoma who undergo a complete resection.
Materials and Methods
Patients
We retrospectively reviewed the records of 565 patients who under-
went thoracic surgery for non–small cell lung cancer between 1992
and 2003 at Osaka University Hospital. Of those, 97 who underwent
a complete resection of a peripheral adenocarcinoma of 2 cm or less
in diameter were enrolled, whereas patients treated with induction
therapy or with multiple primary lesions were excluded. None
were indicated for a mediastinoscopy. The patient characteristics
are shown in Table 1. Postoperative follow-up was completed in
90 patients, and the mean follow-up period was 55 months. Prethor-
acotomy histologic diagnosis was obtained in 69 (70%) patients: in
43 by using a CT-guided percutaneous needle biopsy, in 25 by using
a transbronchial lung biopsy, and in 1 by using sputum cytology. A
lobectomy with systematic hilar and mediastinal lymph node dissec-
tion was performed in principle. A limited resection was indicated
for poor-risk cases, including patients with low pulmonary function,
cardiovascular comorbidity, advanced age, and severe diabetes mel-
litus, as well as for those with a pure GGO lesion smaller than 1.5 cm
in diameter. Postoperative staging was performed according to
TNM classification.11
Histologic Evaluation
Informed written consent for research use of the surgical speci-
mens was obtained from all of the patients. Surgically resected
specimens were fixed in 10% formalin and routinely processed
for paraffin embedding. Histologic sections were cut into 4-mmThe Journal of Thorslices, stained with hematoxylin and eosin, and reviewed by 2 pa-
thologists (T.T. and T.N.), who evaluated the presence of micro-
scopic necrosis. Immunohistochemical studies of the paraffin
sections were also performed by using the Envision1 system
(DAKO, Carpinteria, Calif) for Ki-67 and CEA (DAKO, Kyoto,
Japan) and a Vectastain ABC kit (Vector Laboratories, Burlin-
game, Calif) for D2-40. Antigen retrieval was performed by heat-
ing the sections after immersion in Target Retrieval Solution, High
pH (DAKO) in a pressure cooker for 15 minutes. In addition,
sections were incubated with primary antibodies (monoclonal an-
tibody for Ki-67 [MIB-1] at a concentration of 1:50 for Ki-67,
II-7 at 1:75 for CEA, and D2-40 at 1:120; DAKO) and then lightly
counterstained with hematoxylin. Immunohistochemistry with the
anti–Ki-67 (clone MIB-1) monoclonal antibody was also per-
formed to estimate the proliferative activity of each tumor, with
neoplastic epithelial cells showing intranuclear staining for Ki-67
judged to be positive. The number of Ki-67–positive cells among
200 tumor cells was counted, and the percentage was used as the
Ki-67 LI. The Ki-67–high group was defined as those with a Ki-67
LI of greater than 5%, whereas the Ki-67–low group had a Ki-67
LI at 5% or lower. CEA expression was graded as negative (2), no
staining observed or membrane staining observed in less than 10%
of tumor cells (weakly positive, 1), weak to moderate complete
membrane staining observed in more than 10% of tumor cells
(strongly positive, 11), and strong complete membrane staining
observed in more than 10% of tumor cells. Lymphatic invasion
was determined to be positive when cancer cells were present sur-
rounded by lymphangioendothelium with D2-40 expression.
Statistical Analyses
Survival probability was calculated by using the Kaplan–Meier
method. The prognostic influence of the variables on survival was
analyzed by using a Wilcoxon test and Cox regression. A c2 or
Fisher exact test was used to compare ratios between 2 groups.
TABLE 1. Characteristics of 97 patients who underwent
complete resection of a small-sized adenocarcinoma
(from our database: 1993–2003)
Age (y) 38–82; average, 63.1
Sex
Male 53
Female 44
Tumor diameter
,1 cm 15
1–1.5 cm 13
1.5–2 cm 69
Mode
Lobectomy 77
Segmentectomy 16
Partial resection 4
p Stage
IA 82
IB 4
IIA 2
IIB 2
IIIA 7acic and Cardiovascular Surgery c Volume 135, Number 4 831
General Thoracic Surgery Inoue et al
G
TSResults
Results of Surgical Intervention
The 5-year overall and disease-free survival rates were 93%
and 90%, respectively. Lymph node metastasis was detected
in 11 (11%) patients, and the pathologic stage was pIA (T1
N0 M0) in 82, IB (T2 N0 M0) in 4, IIA (T1 N1 M0) in 2,
IIB (T2 N1 M0) in 2, and IIIA (T1 N2 M0) in 7 (Table 2).
The 5-year disease-free survival rate was 95% for patients
without lymph node metastasis, which was better than that
(59%) for patients with nodal involvement (P , .001). Ac-
cording to tumor diameter, the 5-year disease-free survival
rate was 100% for patients with a tumor of 1 cm or less in di-
ameter, 92% for those with a tumor of 1 to 1.5 cm in diameter,
and 89% for those with a tumor of 1.5 to 2 cm in diameter.
Microscopic Necrosis
Irrespective of the presence or absence of necrosis recognized
at a macroscopic level, tumor cell necrosis was present at the
microscopic level in 17 (18%) patients (Figure 1, A). Among
those patients with necrotic findings in the tumor, 5 (29%)
had lymph node metastasis, whereas only 6 (8%) of the 78
patients without necrotic findings showed nodal involvement
(P 5 .022, Table 2). The 5-year disease-free survival for pa-
tients with microscopic necrosis in the tumor was 68%,
which was significantly worse than that for patients without
necrosis (P , .001; Figure 2, A). Analysis of the 82 patients
with stage IA disease without nodal involvement showed
a significant difference in regard to disease-free period be-
tween those with positive and negative results for necrosis
(P 5 .035; Figure 2, B).
Ki-67 LI
Ki-67 values varied from no staining to more than 30% pos-
itive cells in small-sized adenocarcinomas. Thirty (31%)
patients had a Ki-67 LI of greater than 5% (Ki-67–high
group), in whom 15 tumors showed a value of greater than
10% (Figure 1, B). Lymph node metastasis was detected in
8 (27%) of the 30 patients in the Ki-67–high group, which
was more frequent compared with that for the Ki-67–low
TABLE 2. Relationships between lymph node metastasis
and microscopic necrosis, Ki-67 labeling index, and serum
carcinoembryonic antigen level
LN positive LN negative P value
Necrosis (1) 5 (29%) 12
Necrosis (2) 6 (8%) 74 .022
Ki-67 LI ,5% 3 (4%) 64
Ki-67 LI .5% 8 (27%) 22 .003
Increased CEA level 6 (25%) 18
Normal CEA level 5 (7%) 68 .025
The cutoff level for serum CEA is 5 ng/mL. The Fisher exact test was used
for statistical analysis. LN, Lymph node, LI, labeling index; CEA, carcino-
embryonic antigen.832 The Journal of Thoracic and Cardiovascular Surgery c Aprgroup (P 5 .003, Table 2). The 5-year disease-free survival
rate for the Ki-67–high group was 76%, which was signifi-
cantly worse than that (99%) for the Ki-67–low group
(P , .001; Figure 3, A). Even after analyzing patients with
stage IA disease without lymph node metastasis, there was
a significant difference in disease-free period between the
Ki-67–high and Ki-67–low groups (P 5 .037; Figure 3, B).
CEA Expression by Means of Immunohistochemistry
and Serum CEA Level
CEA expression varied from negative to moderately and
strongly positive (Figure 1, C). In immunohistochemistry re-
sults tumor cells expressed CEA in 72 (74%) of the patients,
among whom 22 (23%) had strongly positive (11) results.
Lymph node metastasis was detected in 5 (23%) of 22 pa-
tients with CEA (11) results and 6 (8%) of 75 patients
with CEA (2) and (1) results (P 5 .118). Furthermore, pa-
tients with an increased serum CEA level had frequent nodal
involvement (Table 2). Prethoracotomy increase of serum
CEA levels was observed in 24 (25%) of 97 patients. Among
those patients, nodal metastasis was detected in 6 (25%),
which was a higher percentage than those with a normal
CEA level (Table 2). Of 13 patients with both increased se-
rum CEA levels and strong CEA staining of the tumors,
5 (38.5%) had lymph node metastasis. In addition, analysis
of the relationship between CEA expression in the tumor
shown by means of immunohistochemistry and preoperative
serum CEA level demonstrated a significant correlation
(Table 3). Strong CEA expression was found in 13 (54%)
of 24 patients with increased serum CEA levels. Conversely,
13 (59%) of 22 patients with CEA (11) expression had an
increase of serum CEA levels. As for disease-free survival,
we found no significant difference between CEA expression
level in the tumor and serum CEA level.
Lymphatic Invasion EvaluatedWithD2-40 Staining of
Lymphangioendothelium
Lymphatic invasion was detected in 18 (19%) of the patients
by using immunohistochemistry with D2-40 for visualizing
lymphatic vessels (Figure 1, D). The 5-year disease-free sur-
vival for those with lymphatic invasion was 77%, which was
significantly worse than that (95%) for patients without lym-
phatic invasion (P , .001; Figure 4, A). When analyzing
patients with stage IA disease without lymph node involve-
ment, the 5-year disease-free survival for those with
lymphatic invasion tended to be poor compared with that
for patients without lymphatic invasion (P5 .061; Figure 4,
B). No significant correlation was found between lymph node
metastasis and lymphatic invasion in the present group of
patients.
Multivariate Analysis for Prognostic Influence
Multivariate analysis with microscopic necrosis, Ki-67 LI,
lymphatic invasion detected with D2-40, serum CEA level,il 2008
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TSFigure 1. A, Microscopic necrosis (arrow): hema-
toxylin and eosin staining, original magnification
340. B, Ki-67 staining: original magnification
340. Top, Few cancer cells were stained with
MIB-1 in this specimen. Immunohistochemistry
results classified the tumor as having a Ki-67 la-
beling index of less than 5% (Ki-67–low group).
Bottom, A proportion of cancer cells was posi-
tively stained. Ki-67 labeling index was judged
as 20% (Ki-67–high group). C, Carcinoembryonic
antigen expression: original magnification 340.
Top, Negative staining; middle, moderate expres-
sion; bottom, strong expression. D, Immunohisto-
chemistry with D2-40 to evaluate lymphatic
invasion: original magnification 340. Lymphatic
invasion by cancer cells was revealed by D2-40
staining of the lymphatic vessels.and p stage as variables identified only lymphatic invasion
as an independent predictor for postoperative recurrence
(Table 4).
Discussion
In the present clinicopathologic study, which focused on
small-sized pulmonary adenocarcinomas of 2 cm or less in
diameter, we identified the presence of microscopic necrosis,
high Ki-67 LI, and increased serum CEA level as predictors
of lymph node metastasis, whereas microscopic necrosis,The Journal of Thorhigher Ki-67 LI, and lymphatic invasion detected with D2-
40 staining were negative factors for disease-free survival.
A lesser pulmonary resection for a peripheral small-sized
lung cancer with careful node exploration has become an ac-
cepted therapy.6,7 However, when serum CEA levels are in-
creased in a preoperative examination or if microscopic
necrosis is found in preoperative biopsy results or intraoper-
ative rapid diagnosis by using frozen sections, a standard op-
eration with a lobectomy with node dissection should be
considered. In addition, patients with a tumor showingacic and Cardiovascular Surgery c Volume 135, Number 4 833
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might be a candidate for adjuvant therapy, even if the lesion is
small and diagnosed as pI.
Kessler and colleagues12 reported that a high percentage
of necrosis was a negative prognostic factor in addition to
blood vessel invasion in patients with resected non–small
cell lung carcinomas, although 66% of those had squamous
cell carcinomas. In another report a significant correlation
of necrosis with T stage, tumor size, or invasiveness was
documented.13 Necrosis is speculated to be caused by
chronic cellular hypoxia as a result of rapid tumor progres-
sion, and thus it is reasonable that necrotic findings have
a negative prognostic effect. In the present study we found
a predictive value of microscopic necrosis for nodal involve-
ment and postoperative disease progression in patients with
a small-sized adenocarcinoma, in whom macroscopic necro-
sis is seldom recognized. Furthermore, in our analysis of pIA
disease, microscopic necrosis was shown to be a useful prog-
nostic factor for recurrence. Because suchmicroscopic necro-
sis can be observed intraoperatively in frozen sections and
rapidly diagnosed, clinical application is expected.
Figure 2. A, Disease-free survival for all patients according to mi-
croscopic findings of necrosis. Patients with necrosis in the tumor
showed a worse outcome compared with those without necrosis.
B, Disease-free survival for patients without nodal metastasis
according to microscopic findings of necrosis. The difference in
the disease-control ratio was statistically significant.834 The Journal of Thoracic and Cardiovascular Surgery c ApKi-67 is generally known as a nuclear protein that is ex-
pressed on various cells in other than the G0 phase of the
cell cycle. A significant correlation between Ki-67 expres-
sion and lymph node metastasis was previously reported
for other malignancies,14,15 and the prognostic significance
of Ki-67 expression for disease-free survival was shown in
cases of resected non–small cell lung cancer.16 As for
Ki-67 expression in early lung cancer, dysplasia and
Figure 3. A, Disease-free survival for all patients according to Ki-
67 labeling index (LI). The Ki-67–high group showed a significantly
worse outcome compared with the Ki-67–low group. B, Disease-
free survival for patients without lymph node metastasis accord-
ing to Ki-67 LI. The difference in the disease-control ratio was
statistically significant.
TABLE 3. Relationship between carcinoembryonic antigen
expression in tumor and preoperative serum carcinoem-
bryonic antigen level
IHC (11) IHC (2) to (1)
Serum increased CEA level 13 11
Serum normal CEA level 9 64
The cutoff level is less than 5 ng/mL. P, .001, Fisher exact test. IHC, Immu-
nohistochemistry for tumor; CEA, carcinoembryonic antigen.ril 2008
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cell carcinoma, and atypical adenomatous hyperplasia have
been analyzed,17,18 although prognostic significance was
not identified in those studies. The present results revealed
that a higher Ki-67 LI in a small-sized adenocarcinoma was
a clinical predictor for both nodal involvement and postoper-
ative recurrence. We also found that Ki-67 LI was a useful
predictor for recurrence in our analysis of patients with pIA
disease. Thus an immunohistochemical evaluation of Ki-67
by using preoperative biopsy materials or resected specimens
would be useful in clinical practice.
We previously reported that the preoperative serum CEA
level can predict nodal involvement in small-sized non–small
cell lung cancer lesions smaller than 2 cm.19 Sawabata and
coworkers20 also noted that lymph node metastasis was
found in 23% of cases of cI non–small cell lung cancer.
Therefore we examined CEA expression in tumors and levels
in serum to identify the utility of CEA measurement as a pre-
dictor for advanced disease in patients with a small-sized pul-
monary lesion. However, local CEA expression levels in the
Figure 4. A, Disease-free survival for all patients according to
lymphatic invasion (Ly) shown by D2-40 immunohistochemistry
results. The Ly (1) group had a significantly worse outcome
compared with the Ly (2) group. B, Disease-free survival for
patients with pIA disease without lymph node metastasis accord-
ing to Ly. Disease-free survival for the Ly (2) group tended to be
better.The Journal of Ttumor had no relationship with nodal metastasis or disease-
free survival in the present cases, although it was reported
in another study that all patients with cI disease with an ade-
nocarcinoma who showed a diffuse expression of CEA had
a poor prognosis and a lower CEA normalization ratio after
surgical intervention.21 We consider that measurement of
serum CEA levels is a more convenient and useful strategy
than immunohistochemical analysis of CEA levels in the
tumor for practical management of patients with a small-
sized adenocarcinoma.
The D2-40 antibody has been recently reported to be more
sensitive for the detection of lymphatic invasion compared
with conventional hematoxylin and eosin staining in several
types of malignancy, such as gastric, breast, colorectal, and
cervical carcinomas.22-25 Although some of those previous
studies revealed a relationship between lymphatic invasion
detected with D2-40 staining and lymph node metastasis,22-24
we found no significant relationship in the present study.
Nevertheless, lymphatic invasion detected with D2-40 stain-
ing had an independent prognostic effect in our cases of
small-sized pulmonary adenocarcinoma. We propose that
D2-40 staining, which is reliable for evaluation of lymphatic
invasion, is useful to predict postoperative relapse in patients
who have undergone resection for a small-sized adenocarci-
noma.
Although we identified several pathologic predictors for
disease relapse in the present study, the preoperative avail-
ability of these useful factors has not been established, which
is the main limitation of this study. Diagnostic imaging, such
TABLE 4. Multivariate analysis of clinicopathologic factors
for postoperative recurrence in patients with resected ad-
enocarcinoma of 2 cm or less in diameter
Variables Hazard ratio 95% CL P value
Microscopic necrosis
Negative 1.000
Positive 2.462 0.596–10.167 .2130
Ki-67 labeling index
,5% 1.000
.5% 3.985 0.708–22.440 .1169
Lymphatic invasion detected
with D2-40 antibody
Negative 1.000
Positive 4.767 1.069–21.264 .0406
Preoperative serum CEA level
WNL 1.000
.5 ng/mL 1.422 0.329–6.136 .6373
p Stage .1094
IA–IB 1.000
IIA–IIB 2.660 0.465–15.233 .2718
IIIA 6.781 1.059–43.425 .0433
CL, Confidence limit; CEA, carcinoembryonic antigen (cutoff value is
5 ng/mL); WNL, within normal limit.horacic and Cardiovascular Surgery c Volume 135, Number 4 835
General Thoracic Surgery Inoue et al
G
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tion regarding oncologic behavior before surgical inter-
vention.26 In addition, gene profiling with DNA-chip
technology might be another methodology to predict the out-
come of patients with resected malignancy. Additional stud-
ies of preoperative diagnosis are required to elucidate the
means to select small-sized adenocarcinomas with malignant
potential.
In summary, histologic findings for microscopic necrosis,
Ki-67 LI, CEA expression, and lymphatic invasion, in addi-
tion to serum CEA level, should be considered for practical
management of patients with a small-sized adenocarcinoma
of the lung.
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